• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Autolus Therapeutics Plc ADR (NQ: AUTL )

    3.990 +0.030 (+0.76%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 493,074
    Open 3.980
    Bid (Size) 3.900 (1)
    Ask (Size) 4.000 (136)
    Prev. Close 3.960
    Today's Range 3.940 - 4.030
    52wk Range 2.010 - 7.450
    Shares Outstanding 52,346,231
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024
    AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire

    Performance

    YTD
    -41.67%
    -41.67%
    1 Month
    -6.99%
    -6.99%
    3 Month
    +1.79%
    +1.79%
    6 Month
    -34.70%
    -34.70%
    1 Year
    +21.65%
    +21.65%

    More News

    Read More
    Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
    Via Benzinga
    Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
    Via Benzinga
    Autolus Therapeutics's Earnings Outlook
    Via Benzinga
    Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
    Via InvestorPlace
    Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Crude Oil Gains 1%; GameStop Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Autolus Therapeutics Announces Changes to its Board of Directors
    From Autolus Therapeutics plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Earnings Scheduled For March 14, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.